Abstract
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is normally expressed in the human immune system and plays a critical role in antitumor immunity. TRAIL interacts with the death receptors, DR4 and DR5, and activates intracellular apoptotic pathway in cancer cells. This discovery has resulted in a rapid development of cancer therapeutic agents that can activate this apoptotic pathway. These therapeutic agents include recombinant human TRAIL (rhTRAIL) and its agonistic monoclonal antibody (MAb) against DR4 and DR5. Phase I trials have established the safety and tolerability of these TRAIL agonists in patients. Phase II trials are currently evaluating the therapeutic efficacy of TRAIL agonists as single agents or in combination with established cancer therapeutics. This review outlines the advances and the challenges in the development of these TRAIL agonists as effective clinical cancer therapeutics.
Keywords: Apoptosis, cancer, death receptor, monoclonal antibody, TRAIL
Reviews on Recent Clinical Trials
Title: TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Volume: 4 Issue: 1
Author(s): Anita C. Bellail, Ling Qi, Patrick Mulligan, Vaninder Chhabra and Chunhai Hao
Affiliation:
Keywords: Apoptosis, cancer, death receptor, monoclonal antibody, TRAIL
Abstract: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is normally expressed in the human immune system and plays a critical role in antitumor immunity. TRAIL interacts with the death receptors, DR4 and DR5, and activates intracellular apoptotic pathway in cancer cells. This discovery has resulted in a rapid development of cancer therapeutic agents that can activate this apoptotic pathway. These therapeutic agents include recombinant human TRAIL (rhTRAIL) and its agonistic monoclonal antibody (MAb) against DR4 and DR5. Phase I trials have established the safety and tolerability of these TRAIL agonists in patients. Phase II trials are currently evaluating the therapeutic efficacy of TRAIL agonists as single agents or in combination with established cancer therapeutics. This review outlines the advances and the challenges in the development of these TRAIL agonists as effective clinical cancer therapeutics.
Export Options
About this article
Cite this article as:
Bellail C. Anita, Qi Ling, Mulligan Patrick, Chhabra Vaninder and Hao Chunhai, TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges, Reviews on Recent Clinical Trials 2009; 4 (1) . https://dx.doi.org/10.2174/157488709787047530
DOI https://dx.doi.org/10.2174/157488709787047530 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
T11TS/SLFA-3 Differentially Regulate the Population of Microglia and Brain Infiltrating Lymphocytes to Reduce Glioma by Modulating Intrinsic Bcl-2 Expression rather than p53
Central Nervous System Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Medical Imaging The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy Tumor Intracellular Redox Status and Drug Resistance-Serendipity or a Causal Relationship?
Current Pharmaceutical Design Luminescent Silica Nanoparticles for Cancer Diagnosis
Current Medicinal Chemistry Conference Report (The XVth International Symposium of Brain Edema and Cellular Injury)
CNS & Neurological Disorders - Drug Targets Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy
Current Medicinal Chemistry VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Nano-Enabled Drug Delivery in Cancer Therapy: Literature Analysis Using the MeSH System
Pharmaceutical Nanotechnology Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Recent Advances in Targeted Therapy for Glioma
Current Medicinal Chemistry Design and Synthesis of Novel Thiosemicarbazones as Potent Anti-breast Cancer Agents
Letters in Drug Design & Discovery